Diabetes & Metabolism Journal

Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial: Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon; Received September 9, 2022 Accepted December 27, 2022 Published online February 9, 2023; DOI: https://doi.org/10.4093/dmj.2022.0315 [Epub ahead of print]; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial: Jae Hyun Bae, Chang Ho Ahn, Ye Seul Yang, Sun Joon Moon, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2022;46(1):71-80. Published online June 16, 2021; DOI: https://doi.org/10.4093/dmj.2020.0274
Cited By 1; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study: Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon; Diabetes Metab J. 2021;45(3):339-348. Published online May 28, 2020; DOI: https://doi.org/10.4093/dmj.2019.0203
Cited By 9; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial: Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi; Diabetes Metab J. 2020;44(4):532-541. Published online November 22, 2019; DOI: https://doi.org/10.4093/dmj.2019.0093
Cited By 7; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial: Kyung-Wan Min, Bon Jeong Ku, Ji-Hyun Lee, Min-Seon Kim, Kyu-Jeung Ahn, Moon-Kyu Lee, Satoshi Kokubo, Satoshi Yoshida, Hyun-Ji Cho, Bong-Soo Cha; Diabetes Metab J. 2017;41(2):135-145. Published online January 11, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.2.135
Cited By 13; Full text PubReader Crossref - TDM PDF

65,535	Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective
65,535	Sex Differences in the Effects of CDKAL1 Variants on Glycemic Control in Diabetic Patients: Findings from the Korean Genome and Epidemiology Study
65,535	Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
16,148	2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
10,201	Insulin Resistance: From Mechanisms to Therapeutic Strategies

Cited By 126	Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status
Cited By 86	2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Cited By 49	Treatment of Diabetic Kidney Disease: Current and Future
Cited By 45	Insulin Resistance: From Mechanisms to Therapeutic Strategies
Cited By 37	Hyperinsulinemia in Obesity, Inflammation, and Cancer

Search